AL-001 Injection for Wet Age-related Macular Degeneration
Long-term Follow-up Study of AL-001 Ophthalmic Injection in Subjects with WAMD
- Age
- 50 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 21 (estimated)
- Sponsor
- Beijing Anlong Biopharmaceutical Co., Ltd. · Industry
This trial is looking for patients who have previously received the AL-001 injection for wet age-related macular degeneration. Participants will help evaluate the long-term safety and effectiveness of this treatment.
You may be able to join if
- I have received the AL-001 ophthalmic injection in a previous study.
- I agree to participate and sign a written consent form.
- I am willing and able to attend scheduled visits and follow procedures.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your EligibilityThis study is designed to evaluate long-term safety and efficacy of AL-001 ophthalmic injection following suprachoroidal space(SCS) administration in subjects with wAMD. Eligible patients, are those who were previously enrolled in a clinical study in which they received a single dose of AL-001 administered via suprachoroidal space injection.
Loading trial locations…